About
Eupraxia Pharmaceuticals Inc (TO:EPRX) — investor relations, events, news, and company updates on 6ix.
Latest News
Apr 22 2026
Eupraxia Pharmaceuticals to Present at Digestive Disease Week Annual Meeting
Apr 21 2026
Eupraxia Pharmaceuticals Reports Positive Nine-Month Tissue Health and Symptom Data from the Highest Dose Cohort in its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis 
Apr 13 2026
Eupraxia Pharmaceuticals to Present at Upcoming Investor Conferences
Mar 17 2026
Eupraxia Pharmaceuticals Reports Six-Month Symptom Data from the Highest Dose Cohort in its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis
Mar 13 2026
Eupraxia Pharmaceuticals Reports Fourth Quarter 2025 Financial Results
Financials
Revenue
CA$0
Market Cap
CA$611.96 M
EPS
-1.43
Google Übersetzer